India making major strides in vaccine development and safety

Even as Panacea Biotec announced its tetravalent vaccine Easyfour-TT for active primary immunization and booster dose against diphtheria, tetanus and pertussis (DTP) and hemophilus influenza type B (Hib), and Cipla has launched its hepatitis B vaccine, India has received a pat on the back from the World Health Organization for its advances in vaccine safety, reports The Pharma Letter’s India correspondent.

With 27 million births every year, the domestic market for vaccines in India is quite huge. The country has been self-sufficient in meeting domestic needs, with the private sector filling in the demand supply gap.

Some of the prominent players in the industry are the Serum institute of India (SII), Bharat Biotech International, Shanta Biotech and Panacea Biotech, among others.